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Abstract 
Distinct Diarrhea Profiles During Outpatient Chemotherapy 
by Rafael Diaz 
Purpose: Chemotherapy-induced diarrhea (CID) is a common symptom that occurs in 50% to 80% of 
patients. Given that the majority of the data on the occurrence and severity of CID is based on physician-
rated toxicity criteria, this study’s purposes were to: identify subgroups of patients with distinct CID 
profiles and determine how these subgroups differ in terms of demographic and clinical characteristics; 
severity, frequency, and distress of CID; the co-occurrence of common GI symptoms, and QOL. 
Methods: Patients (n=1133) completed the Memorial Symptom Assessment Scale six times over two 
cycles of chemotherapy (CTX). Latent profile analysis was used to identify subgroups of patients with 
distinct diarrhea profiles. Differences among these subgroups were evaluated using parametric and 
nonparametric statistics. 
Results: Four distinct diarrhea profiles were identified: none (58.3%), decreasing (22.0%), increasing 
(5.2%), and high (14.5%). Compared to the none class, patients in the high class had a lower functional 
status, a worse comorbidity profile, were more likely to have gastrointestinal cancer, and were more likely 
to receive CTX on a 14 day cycle. No differences were found among the classes in the percentages of 
patients who received CTX with a targeted therapy. 
Conclusion: Given that CID occurred in over 40% of the patients, clinicians should assess for this 
symptom and other common GI symptoms and initiate appropriate pharmacologic and dietary 
interventions. 
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Introduction 
Chemotherapy-induced diarrhea (CID) is a common symptom that occurs in 50% to 80% of 
patients [33]. While the mechanisms that underlie CID are not well understood, it is defined as an 
increase in the frequency, above a patient’s baseline, of soft, loose, and watery stool [14]. Most of the 
prevalence rates for CID are derived from studies that used the National Cancer Institute’s (NCI) 
Common Toxicity Criteria for Adverse Events (CTCAE) to grade CID based on its frequency and 
severity [1,3,27]. 
While CID is most commonly associated with the administration of fluoropyrimidines, irinotecan, 
and capecitabine, it can occur with most of the chemotherapy (CTX) drugs that are used to treat the 
majority of solid tumors (e.g., cisplatin, methotrexate, doxorubicin, paclitaxel, docetaxel) [1,17]. In 
addition, CID occurs with the administration of targeted therapies (e.g., tyrosine-kinase inhibitors (TKIs), 
inhibitors of the mammalian target of rapamycin (m-TOR), and epidermal growth factor receptor (EGFR) 
targeted therapies) [1,17,27,33]. More severe CID (i.e., CTCAE grades 3 and 4) is associated with the 
administration of combination CTX with or without targeted therapy [1,17,27,33].  
While studies are limited, some of the identified risk factors for CID include: older age (>65 
years), being female, being White, having a lower performance status, previous episodes of CID, specific 
cancer diagnoses (e.g., gastrointestinal (GI)), history of bowel problems (e.g., inflammatory bowel 
disease, malabsorption), and diabetes mellitus [1,4,24,31,34]. In addition, polymorphisms in genes that 
are associated with the metabolism of fluoropyrimidines contribute to increased toxicity including CID 
[16]. 
Given that the mechanisms that underlie the development of CID (e.g., inflammation, apoptosis), 
involve the entire GI tract [15,17,33], it is not surprising that CID can co-occur with other GI symptoms. 
While clinical experience suggests that CID is associated with nausea, vomiting, anorexia, and abdominal 
cramps [37], limited evidence suggests that in oncology outpatients receiving CTX, nausea [30] and 
changes in the way food tastes [21] are associated with the co-occurrence of CID. 
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The consequences of severe CID can be significant and include dose reductions, delays in CTX 
treatments, discontinuation of CTX, or hospitalization [17,27]. In addition, CID can have a negative 
impact on patients’ quality of life (QOL) including higher levels of anxiety, depression, and malnutrition, 
as well as decreases in performance status and ability to perform routine activities of daily living [1,37]. 
More recently, in a systematic review of the economic implications of CID and its impact on QOL [36], 
the authors concluded that CID (i.e., Grades 3 and 4) had a profound impact on patients’ QOL. However, 
they noted that only two of the twenty-two studies reviewed, had CID as the primary study outcome 
[26,40]. 
Given that the majority of the data on the occurrence and severity of CID is based on physician-
rated CTCAE criteria, as well as the paucity of research on: risk factors for CID; the co-occurrence rates 
of other GI symptoms with CID; and the impact of CID on patients’ QOL, “real world” studies (i.e., data 
obtained outside the context of randomized clinical trials and generated during routine clinical practice) 
are needed to better understand this adverse effect of CTX. Therefore, the purposes of this study, in a 
sample of oncology outpatients undergoing CTX (n=1133), were to: identify subgroups of patients with 
distinct CID profiles and determine how these subgroups differed in terms of demographic and clinical 
characteristics; severity, frequency, and distress of CID; the co-occurrence of common GI symptoms, and 
QOL. 
Methods 
Patients and settings 
This analysis is part of a larger, longitudinal study, funded by the National Cancer Institute, of the 
symptom experience of oncology outpatients receiving CTX [18,39]. Eligible patients were ≥18 years; 
had a diagnosis of breast, GI, gynecological, or lung cancer; had received CTX within the preceding four 
weeks; were scheduled to receive at least two additional cycles of CTX; were able to read, write, and 
understand English; and provided written informed consent. Patients were recruited from two 
Comprehensive Cancer Centers, one Veteran’s Affairs hospital, and four community-based oncology 
programs. 
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Study procedures 
The study was approved by the Institutional Review Board at each of the study sites. Of the 2234 
patients approached, 1343 consented to participate and 1133 had evaluable data on CID for this analysis. 
Patients’ refusal to participate was primarily due to being overwhelmed with their cancer treatment. 
Eligible patients were approached in the infusion unit during their first or second cycle of CTX to discuss 
participation in the study. Patients completed study questionnaires in their homes, a total of six times over 
two cycles of CTX, namely: prior to CTX administration (i.e., recovery from previous CTX cycle; 
Assessments 1 and 4), approximately 1 week after CTX administration (i.e., acute symptoms; 
Assessments 2 and 5), and approximately 2 weeks after CTX administration (i.e., potential nadir; 
Assessments 3 and 6). Medical records were reviewed for disease and treatment information. 
Instruments 
Demographic and clinical characteristics – Patients completed a demographic questionnaire, Karnofsky 
Performance Status (KPS) scale [13], Self-Administered Comorbidity Questionnaire (SCQ) [29], 
Alchohol Use Disorders Identification Test [2], and a smoking history questionnaire. 
Assessment of diarrhea occurrence – The diarrhea item from the Memorial Symptom Assessment Scale 
(MSAS) was used to assess for the occurrence of CID at each of the six assessments. The MSAS is a 
valid and reliable symptom assessment instrument that evaluates the occurrence, severity, frequency, and 
distress of 32 common symptoms [23]. 
Assessment of additional GI symptoms - The occurrence rates for ten additional GI symptoms (i.e., dry 
mouth, nausea, feeling bloated, vomiting, lack of appetite, abdominal cramps, difficulty swallowing, 
mouth sores, weight loss, change in the way food tastes) were evaluated using the MSAS. Data from the 
enrollment assessment were used to evaluate the co-occurrence of these common GI symptoms with CID. 
Quality of life instruments – Generic and disease-specific measures of QOL were used in this study. The 
Medical Outcomes Study–Short Form (SF-12) was the generic measure of QOL. The SF-12 consists of 
12 questions about physical and mental health as well as overall health status. The SF-12 was scored into 
two components that measure physical (i.e., Physical Component Summary (PCS)) and psychological 
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(Mental Component Summary (MCS)) function. These scores can range from 0 to 100. Higher PCS and 
MCS scores indicate better physical and psychological functioning, respectively. The SF-12 has well 
established validity and reliability [38]. 
Disease-specific QOL was evaluated using the Quality of Life Scale-Patient Version (QOL-PV)) 
[22]. This 41-item instrument measures four domains of QOL (i.e., physical, psychological, social, 
spiritual well-being) in oncology patients, as well as a total QOL score. The QOL-PV has well established 
validity and reliability [9]. 
Coding of the CTX regimens 
 Given the diversity in the cancer diagnoses and absolute number of different CTX regimens, each 
patient’s regimen was coded as follows: received only CTX, received only targeted therapy, or received 
both CTX and targeted therapy. 
Coding of the emetogenicity of the CTX regimens 
Using the Multinational Association of Supportive Care in Cancer guidelines [25], each CTX 
drug was classified as having: minimal, low, moderate, or high emetogenic potential. Emetogenicity of 
the regimen was categorized into one of three groups (i.e., low/minimal, moderate, high) based on the 
CTX drug with highest emetogenic potential. 
Coding of the antiemetic regimens 
Each antiemetic was coded as either a neurokinin-1 (NK-1) receptor antagonist, a serotonin 
receptor antagonist, a dopamine receptor antagonist, prochlorperazine, lorazepam, or a steroid. The 
antiemetic regimens were coded into one of four groups: none (i.e., no antiemetics administered); steroid 
alone or serotonin receptor antagonist alone; serotonin receptor antagonist and steroid; or NK-1 receptor 
antagonist and two other antiemetics (e.g., serotonin receptor antagonist, dopamine receptor antagonist, 
prochlorperazine, lorazepam and/or a steroid). 
Data analyses 
Descriptive statistics and frequency distributions were generated for sample characteristics at 
enrollment using the Statistical Package for the Social Sciences (SPSS) version 23 [32].  
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As was done for other symptoms [5,6], unconditional latent class analysis (LCA) was used to 
identify the profiles of CID occurrence that characterized unobserved subgroups of patients (i.e., latent 
classes) over the six assessments. Prior to performing the LCA, patients who responded “no” to the 
diarrhea item on the MSAS for five (n=205) or six (n=456) assessments (i.e., these patients did not 
experience diarrhea across the two cycles of CTX) were identified and labelled as the “none” class 
(n=661). Then, the LCA was performed on the remaining 472 patients. 
Estimation was carried out with full information maximum likelihood with standard errors and a 
Chi-square test that are robust to non-normality and non-independence of observations 
(“estimator=MLR”) using a logit link because the items are binary. Model fit was evaluated to identify 
the solution that best characterized the observed latent class structure with the Bayesian Information 
Criterion (BIC), Vuong-Lo-Mendell-Rubin likelihood ratio test (VLRM), entropy, and latent class 
percentages that were large enough to be reliable (i.e., likely to replicate in new samples) [20]. Missing 
data were accommodated for with the use of the Expectation-Maximization (EM) algorithm [19]. Mixture 
models, like LCA, are known to produce solutions at local maxima. Therefore, our models were fit with 
from 800 to 2,400 random starts. This approach ensured that the estimated model was replicated many 
times and was not due to a local maximum. Estimation was done with Mplus Version 8.2 [20]. 
Differences among the latent classes in demographic, clinical, and symptom characteristics, as 
well as QOL outcomes were evaluated using analysis of variance and Kruskal-Wallis or Chi Square tests. 
A p-value of <.05 was considered statistically significant. Post hoc contrasts were done using a 
Bonferroni corrected p-value of <.008 (.05/4 pairwise comparisons). 
Results 
Latent class analysis 
The 661 patients (58.3%) who had ≤1 occurrence of CID over the six assessments were classified 
as the none class. For the remaining 472 patients whose data were entered into the LCA, a three class 
solution was selected because its BIC was smaller than the BICs for the 2-class and 4-class solutions 
(Table 1). In addition, the VLRM was significant for the 3-class solution, but not for the 4-class solution, 
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which indicates that too many classes were extracted. As shown in Figure 1, the trajectories for the 
occurrence of CID differed among these latent classes. For the decreasing class (22.0%), the occurrence 
rate for CID increased slightly from the first to the second assessment, then gradually decreased over the 
remaining four assessments. For the increasing class (5.2%), the occurrence rates for CID were relatively 
low over the first three assessments and then increased dramatically over the fourth and fifth assessments. 
For the high class (14.5%), the occurrence rates for CID remained consistently high over the six 
assessments.  
Demographic and clinical characteristics 
As shown in Table 2, for most of the demographic characteristics, no differences were found 
among latent classes. Compared to the high class, patients in the increasing class were more likely to be 
married. In terms of clinical characteristics, compared to the none class, patients in the high class had 
significantly lower KPS scores, higher SCQ scores, were more likely to report depression and diabetes, 
were more likely to have GI cancer and less likely to have breast or lung cancer, were more likely to 
receive CTX on a 14-day cycle, and were more likely to receive moderately emetogenic CTX. Compared 
to the none class, patients in the decreasing class had lower KPS scores, higher MAX2 scores, and were 
more likely to report ulcer/stomach disease. Compared to the none class, patients in the increasing class 
were more likely to report diabetes. 
Frequency, severity, and distress of CID at enrollment 
 As shown in Figure 2A, significant differences were found among the classes in the frequency of 
CID (p<.001). Post hoc contrasts found that compared to the increasing and decreasing classes, the 
patients in the high class reported a higher frequency of CID. In terms of severity (Figure 2B), significant 
differences were found among the classes (p<.001). Post hoc contrasts found that compared to the 
increasing and decreasing classes, patients in the high class had more severe CID. In addition, compared 
to the increasing class, patients in the decreasing class had more severe CID. In terms of distress (Figure 
2C), significant differences were found among the classes (p<.001). Post hoc contrasts found that 
compared to the increasing and decreasing classes, patients in the high class reported higher distress 
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ratings for CID. In addition, compared to the increasing class, patients in the decreasing class reported 
higher distress ratings for CID. 
Occurrence of GI symptoms at enrollment 
As shown in Table 3, compared to the none class, patients in the high class reported higher 
occurrence rates for: dry mouth, nausea, feeling bloated, vomiting, lack of appetite, abdominal cramps, 
difficulty swallowing, mouth sores, weight loss, and change in way food tastes. Compared to the none 
class, patients in the decreasing class reported higher occurrence rates for: nausea, feeling bloated, lack of 
appetite, abdominal cramps, and increased appetite. Compared to the high class, patients in the increasing 
class reported lower occurrence rates for nausea and abdominal cramps. 
QOL scores 
As shown on Table 4, for the SF-12, compared to the none class, patients in the high class had 
lower scores for: role physical, general health, vitality, social functioning, mental health, and MCS. 
Compared to the none class, patients in the decreasing class had lower scores for: physical functioning, 
role physical, bodily pain, vitality, social functioning, role emotional, mental health, as well as PCS and 
MCS.  
For the MQOLS-PV, compared to the none class, patients in the decreasing and high classes had 
lower scores for: physical well-being, psychological well-being, and total QOL. In addition, compared to 
the none class, patients in the high class had lower scores for social well-being. 
Discussion 
This study is the first to use LCA to identify subgroups of patients with distinct CID profiles; 
categorize its frequency, severity and distress; describe the co-occurrence of GI symptoms; and describe 
the impact on CID on patients’ QOL. While previous clinical trials reported prevalence rates of between 
50% and 80% [33], 42% of our patients reported the occurrence of CID over the six assessments. Of note, 
14.5% of our sample had high rates of diarrhea across the two cycles of CTX. In addition, for the majority 
of the patients in the high class, the frequency, severity and distress associated with CID were in the two 
highest ranges of each scale (Figure 2). 
	 8	
One of the objectives of this study was to identify risk factors associated with the occurrence of 
CID. While findings from previous studies suggest that older age, being female, and being White were 
associated with the occurrence of CID [1,34], the only demographic characteristic that was identified in 
our study was that compared to the increasing group, the high group was less likely to be married or 
partnered. Reasons for these inconsistent findings may be related to the heterogeneity in the patients’ 
cancer diagnoses, heterogeneity in CTX regimens, and/or the use of self-report versus clinician-rated 
measures of CID. 
In terms of clinical risk factors, consistent with one review [24], compared to the none class, 
patients in the increasing and high classes had a poorer functional status. In addition, compared to the 
none class, patients in the high class had a higher level of comorbidity. Of note, the specific comorbidities 
that differentiated between the none and the high classes were diabetes and depression. In one review that 
summarized information on fluorouracil-induced CID in patients with GI cancers [1], diabetes mellitus 
was a risk factor for CID. Given that severe CID can result in dehydration and electrolyte imbalances, 
patients with these risk factors as well as with GI and renal disorders warrant ongoing clinical evaluation. 
Most of the studies of CID have focused on specific CTX regimens and methods of drug 
administration [3,24]. Given the heterogeneity in the CTX regimens used in this study, as well as the 
previously reported high prevalence rates of diarrhea across combination CTX regimens with or without a 
targeted therapy [1,17,27,33], we categorized the CTX regimens in two ways (i.e., receipt of targeted 
therapy (yes/no); receipt of only CTX, only targeted therapy, or both CTX and targeted therapy). Quite 
surprisingly, in our study, no differences were found among the four classes in either of these 
categorizations. In addition, when this analysis was repeated within each cancer diagnosis, these findings 
remained consistent. Future studies need to evaluate for molecular mechanisms that may predispose 
patients to CID independent of the CTX regimen (e.g., GI inflammation, disruption of the gut 
microbiome). 
While the CTX regimens themselves were not associated with latent class membership, a larger 
percentage of patients with GI cancers were categorized in the high class. This finding is not surprising 
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given that CTX regimens, like fluorouracil and irinotecan, used to treat GI cancers are associated with an 
increased risk of CID [1]. However, it should be noted that almost 37.5% of the patients with breast 
cancer, 40.5% of the patients with gynecological cancer, and 20.5% of the patients with lung cancer were 
categorized in one of the CID classes. These findings suggest that this symptom warrants ongoing 
assessment and management during CTX. 
While the toxicity of the CTX regimens, that was assessed using the MAX2 score [7,8], only 
differed between the none and decreasing class, cycle length was a risk factor for CID. As noted in one 
review [24], findings regarding differences in the occurrence rates of severe CID associated with the 
administration of irinotecan every two versus every three weeks are inconclusive. In our study, compared 
to the none and decreasing classes, a larger percentage of patients in the high class received CTX on a 14-
day cycle.  
Our findings regarding the significantly higher co-occurrence rates for eleven common GI 
symptoms in the high compared to the none class adds to the growing body of literature on the 
identification of a GI symptom cluster in patients with breast [35], lung [28], GI [11], and gynecological 
[12] cancers. In addition, across all four CID classes, greater than 40% of the patients reported the 
occurrence of dry mouth, nausea, and change in the way food tastes prior to their second or third cycle of 
CTX. As noted in two reviews [10,17], this constellation of symptoms may be related to the direct effects 
of CTX on the epithelial cells that line the entire GI tract. CTX acts directly on these rapidly dividing 
cells which results in apoptosis, the release of pro-inflammatory cytokines, GI inflammation, and 
disruption of the gut microbiome. While pain and fatigue are routinely assessed in clinical practice, 
findings from this study, as well as our previous studies [21,30], suggest that clinicians need to perform a 
systematic assessment of multiple GI symptoms and initiate appropriate interventions. 
 Consistent with previous reports [1,37], the occurrence of CID had a significant negative impact 
on both generic and disease-specific domains of QOL. While the scores for the majority of the QOL 
domains were relatively similar among the decreasing, increasing, and high classes (Table 4), statistically 
significant and clinically meaningful differences in these QOL scores were found between the none class 
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and the decreasing and/or high classes. The lack of significant differences associated with membership in 
the increasing class may be related to its relatively small sample size. Findings from our study suggest 
that CID has a negative impact on the physical, psychological, and social domains of QOL.  
Limitations 
 Several limitations warrant consideration. Given that patients reported the occurrence of CID 
prior to their second or third cycle of CTX, future studies need to obtain a detailed history of previous 
episodes of CID and irritable bowel disease. Given that patients were assessed for only two cycles of 
CTX, the duration of CID or worsening of CID with subsequent cycles were not evaluated. Given the 
heterogeneity in this “real world” sample, in terms of cancer diagnoses and CTX regimens, replication of 
these distinct CID profiles is warranted with more homogenous samples. Future studies need to evaluate 
for the pharmacologic and nonpharmacologic treatments that patients used to manage their CID. Finally, 
given the fact that the types of CTX regimens were not associated with the distinct CID profiles, future 
studies need to account for molecular mechanisms that may place patients at higher risk for CID 
regardless of their CTX regimen. 
Conclusions 
 Despite these limitations, findings from this large sample of oncology outpatients, who were 
followed over two cycles of CTX provides useful information for clinicians. While only 14.5% of the 
patients were in the high class, CID occurred in over 40% of the patients in our sample. Clinicians should 
be mindful of the risk factors identified in this study including: higher level of comorbidity, occurrence of 
diabetes and depression, diagnosis of GI cancer, receipt of CTX on a 14-day cycle, and lower functional 
status during their assessments of patients. Given the high prevalence of other GI symptoms with CID and 
their potential impact on patients’ nutritional and hydration status, referrals to a dietician may be 
warranted particularly for the patients in the high class. 
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Figure 1 – Chemotherapy-induced diarrhea trajectories for patients in each of the latent classes 
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Figure 2 – Percentage of patients in the decreasing, increasing, and high who rated the frequency (A), 
severity (B), and distress (C) associated with chemotherapy-induced diarrhea.  
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Table 1 - Solutions and Fit Indices for One- Through Four-Classes for Diarrhea Occurrence Latent 
Profile Analyses 
 
Model                  LL               AIC  BIC  VLMR           Entropy 
     
 
1 Class -1665.28 3342.56 3367.50 n/a                        n/a 
 
2 Class -1602.57 3231.14 3285.18 125.42*** .61 
 
3 Classa  -1575.92 3191.84 3274.98 53.31*** .64 
 
4 Class  -1564.99 3183.99 3296.22 21.85ns .69 
 
 
***p < .001  
 
aThe 3-class solution was selected because the BIC was smaller than the BICs for both the 2-class and 4-
class solutions. In addition, the VLMR was significant for the 3-class solution, indicating that three 
classes fit the data better than two classes. However, the VLMR was not significant for the 4-class 
solution, indicating that too many classes had been extracted. 
 
Abbreviations: AIC = Akaike Information Criterion, BIC = Bayesian Information Criterion, LL = log-
likelihood, n/a = not applicable, ns = not significant, VLMR = Vuong-Lo-Mendell-Rubin likelihood ratio 
test for the K vs. K-1 model 
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